Published by Independent Med Management (IMM)  |  Reading time: 5 minutes

For over a decade, Independent Med Management (IMM) has partnered with Australia’s leading personal injury insurers to deliver clinical pharmacy intelligence that directly supports claims decision-making. Our services have become embedded in the operational workflows of Workers’ Compensation and CTP teams across the country, and we take that trust seriously.

This article is a service clarification for Allianz CTP teams specifically, and a broader update for all IMM clients and prospective partners on the current state of our service model.

Allianz CTP: Your Current Service Arrangements

As of April 2026, Allianz CTP continues to operate under IMM’s legacy service model. This means the two services currently available to your teams are:

Until further notice, these services remain your active service selections. There is no action required from your teams at this stage. If and when any changes are made to your service arrangements, IMM will communicate directly with your relevant stakeholders well in advance of any transition.

What Is a Primary Assessment?

The Primary Assessment is IMM’s flagship clinical pharmacy review. It is a comprehensive, pharmacist-led analysis of a claimant’s entire medication profile, designed to give case managers, claims officers, and technical specialists a clear, clinically grounded picture of what is happening across a claimant’s treatment.

In practical terms, a Primary Assessment delivers:

• Full medication profile review: Every dispensed medication is identified, classified by drug class, and assessed for clinical appropriateness, including dose, frequency, and duration of therapy.
• Risk identification: Medications carrying elevated clinical risk are flagged and categorised. This includes high-risk combinations, medications with dependency potential, therapeutic duplication, and prescribing patterns that fall outside clinical guidelines.
• Drug interaction analysis: Clinically significant interactions between concurrent medications are identified and graded by severity, giving teams an immediate understanding of where intervention may be needed.
• Plain-language reporting: Every finding is translated into clear, non-clinical language so that operational teams can act on the information without requiring a clinical background.
• Actionable recommendations: Each assessment concludes with prioritised, practical recommendations that can be incorporated directly into claims strategy discussions, file reviews, or treating doctor correspondence.

The Primary Assessment is not a tick-box exercise. It is a detailed clinical document, prepared by a registered pharmacist with expertise in personal injury pharmacy, and tailored to the specific context of each claim. This is what sets it apart from generic medication reviews available elsewhere in the market.

Why Teams Rely on the Primary Assessment

Case managers and claims teams operate under significant time pressure. They manage large portfolios, navigate complex treatment histories, and are expected to make decisions that are clinically informed, even when clinical expertise is not their primary skill set. The Primary Assessment exists to bridge that gap.

Clarity in Complex Claims

Many claims involve claimants on 10, 15, or even 20+ concurrent medications. Trying to interpret that volume of dispensing data without clinical support is time-consuming and carries risk. The Primary Assessment distils that complexity into a structured, prioritised report that gives teams confidence in their next steps.

Early Identification of Risk

One of the most consistent pieces of feedback from our insurer partners is that the Primary Assessment surfaces risks they would not have otherwise identified. Opioid escalation patterns, benzodiazepine dependency indicators, serotonin syndrome risk from antidepressant combinations: these are findings that materially change claims outcomes when identified early.

Supporting Conversations with Treating Practitioners

The Primary Assessment gives case managers a clinical evidence base to support conversations with treating doctors, specialists, and allied health providers. Rather than approaching a prescriber with vague concerns, teams can reference specific findings from a pharmacist-prepared report. This elevates the quality of engagement and, in many cases, leads to direct prescriber action.

Demonstrated Impact on Claims Costs

Across IMM’s client base, the Primary Assessment has consistently demonstrated measurable impact. An 81% prescriber implementation rate on our recommendations means that the clinical intelligence generated by these reviews is not sitting in a file. It is being actioned by treating practitioners, driving medication optimisation, reducing unnecessary spend, and improving claimant health outcomes.

Industry-Leading, Nationally Established

IMM’s clinical pharmacy review services are not new to the market. We have built and refined this capability over more than a decade of direct partnership with Australia’s major personal injury insurers. Our pharmacist team delivers reviews across Workers’ Compensation and CTP portfolios nationally, and our processes are deeply integrated into the operational workflows of some of the largest claims teams in the country.

Key facts about IMM’s service delivery:

• Established partnerships with all major personal injury insurers across Australia
• Dedicated pharmacist team with specialised expertise in personal injury pharmacy and medication risk governance
• 81% prescriber implementation rate on clinical recommendations, validated across thousands of completed reviews
• National coverage across all Australian states and territories

This is not a service that is being tested or trialled. It is proven, embedded, and trusted by the teams that use it every day.

Updated Services Now Available for Other Insurers

While Allianz CTP continues to operate under the legacy service model, IMM has been actively developing and refining an expanded suite of clinical pharmacy services. These updated services reflect the evolving needs of personal injury insurers and incorporate new capabilities, streamlined reporting formats, and revised pricing structures.

Insurers outside of the current Allianz CTP arrangement are now able to access these updated services. Whether you are an existing IMM client looking to explore the latest offerings, or a new organisation considering clinical pharmacy review as part of your claims management strategy, we welcome the conversation.

Summary

For Allianz CTP, nothing changes right now. Your teams continue to access IMM’s Primary Assessment and Liability services under the existing legacy arrangements. These services remain fully supported, delivered by the same experienced pharmacist team, and held to the same clinical standards that have made them a trusted part of your claims workflow.

For all other insurers and prospective partners, IMM’s updated services and pricing are now available. We encourage you to get in touch to explore how clinical pharmacy intelligence can strengthen your claims outcomes.

As always, if you have any questions about your current service arrangements or would like to discuss your options, please contact your IMM account manager or reach out to us directly.

Independent Med Management (IMM) provides pharmacy review and medication risk governance services to Workers’ Compensation and CTP insurers across Australia. This article is for general information purposes. Clinical decisions should be made in consultation with qualified health professionals.